A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial.

Rieß, H.; Pelzer, Uwe; Opitz, Bernhard; Stauch, Martina; Reitzig, P; Hahnfeld, S.; Müller, Lara; Stieler, Jens; Dörken, Bernd; Oettle, Helmut

doi:10.1200/jco.2010.28.15_suppl.4033

Cited by 60 publications

(33 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…163 Furthermore, in the randomized CONKO-004 trial, the symptomatic VTE rate for patients with pancreatic cancer receiving chemotherapy was significantly reduced at 3 and 12 months with enoxaparin thromboprophylaxis (1 mg/ kg daily for 3 months followed by 40 mg daily for 3 months) compared with no LMWH. 164 Most recently, a large phase III randomized placebo-controlled trial (SAVE-ONCO) in patients with advanced cancer receiving chemotherapy (N=3212) compared thromboprophylaxis with the investigational ultra-LMWH semuloparin, 20 mg daily, versus placebo. 165 The primary efficacy end point of this study was a composite end point comprising symptomatic DVT, nonfatal or fatal PE, and other death related to VTE.…”

Section: Vte Prophylaxismentioning

confidence: 99%

Venous Thromboembolic Disease

Streiff¹,

Bockenstedt²,

Cataland³

et al. 2013

J Natl Compr Canc Netw

View full text Add to dashboard Cite

OverviewVenous thromboembolism (VTE) is a common and life-threatening condition in patients with cancer.1,2 Results from a retrospective study of hospitalized adult patients with cancer with neutropenia (N=66,106) showed that approximately 3% to 12% of these patients, depending on the type of malignancy, experienced VTE during their first hospitalization.1 In a recent health claims database analysis of patients undergoing chemotherapy for solid tumors in the ambulatory setting (N=17,284), VTE NCCN Venous Thromboembolic Disease Clinical Practice Guidelines in Oncology AbstractVenous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer. (JNCCN 2013;11:1402-1429 NCCN Categories of Evidence and ConsensusCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. These guidelines are also available on the Internet. For the latest update, visit NCCN.org.

show abstract

Section: Vte Prophylaxismentioning

confidence: 99%

Venous Thromboembolic Disease

Streiff¹,

Bockenstedt²,

Cataland³

et al. 2013

J Natl Compr Canc Netw

View full text Add to dashboard Cite

show abstract

“…There were no significant major hemorrhagic complications in both groups. The median overall survival was not different between the two groups (9.92 month in treated patients versus 8.15 month in no treatment group; p=0.054), for a median follow up period of 45.44 months (Reiss et al, 2010).…”

Section: Prophylaxis Of Venous Trombosismentioning

confidence: 94%

Coagulation Disorders in Pancreatic Cancer

Albu¹,

Gheban²,

Grad³

et al. 2012

Pancreatic Cancer - Clinical Management

View full text Add to dashboard Cite

“…In Anbetracht der eingangs aufgeführten Entwicklungen in der Tumortherapie sowie der Tatsache, dass sich diese zunehmend vom stationären in den ambulanten Bereich verlagert, stellen VTE aber auch für ambulante Patienten ein relevantes Problem dar. Daher haben sich inzwischen mehrere klinische Studien mit der Thromboseprophylaxe in diesem Kollektiv befasst [1,2,12,15] [3,7].…”

Section: Leitlinien ▼unclassified

Prophylaxe und Therapie venöser Thromboembolien bei Tumorpatienten

Struve

Cm²

2012

Dtsch med Wochenschr

View full text Add to dashboard Cite

A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial.

Cited by 60 publications

References 0 publications

Venous Thromboembolic Disease

Venous Thromboembolic Disease

Coagulation Disorders in Pancreatic Cancer

Prophylaxe und Therapie venöser Thromboembolien bei Tumorpatienten

Contact Info

Product

Resources

About